Limited Stage Small Cell Lung Cancer Clinical Trial
Official title:
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Single-arm, Phase 2 Trial
For limited-stage small cell lung cancer (SCLC), neoadjuvant chemotherapy plus PD-1 antibody is recommended. However, most patients cannot achieve a complete pathological response (CPR). A new immunotherapeutic strategy is needed to achieve a higher CPR rate. JS004 is a new antibody targeting B and T lymphocyte attenuator (BTLA), which restrains immune cells' function and leads to immune escape of tumor cells. The combination of PD-1 and BTLA antibodies has shown a good therapeutic effect in solid tumors. This trial aims to investigate the efficacy and safety of the therapeutic regimen of toripalimab and JS004 plus etoposide and platinum Chemotherapy in limited-stage SCLC.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01935336 -
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
|
Phase 2 | |
| Recruiting |
NCT05443646 -
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
|
Phase 2 | |
| Completed |
NCT00066742 -
Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05034133 -
Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT04790253 -
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
|
N/A | |
| Recruiting |
NCT05942508 -
A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy
|
Phase 1 | |
| Completed |
NCT00019006 -
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05483543 -
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy
|
Phase 2 | |
| Active, not recruiting |
NCT02046733 -
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
|
Phase 2 | |
| Completed |
NCT04952597 -
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05623267 -
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
|
Phase 2/Phase 3 | |
| Completed |
NCT01457469 -
Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT06117774 -
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
|
Phase 3 | |
| Completed |
NCT01999881 -
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
|
N/A | |
| Not yet recruiting |
NCT05496166 -
The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04829708 -
Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy
|
Phase 3 | |
| Completed |
NCT00470054 -
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00084487 -
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
|
Phase 2 |